FibroBiologics, Inc. FBLG
0.94 USD -0.02 (-1.63%)
Nov 6, 2026, 11:23 AM EST
0.9111 Day range 0.97
0.62 52-week range 9.60
- YTD
- -79.02%
- 1 year
- -85.91%
- Market cap
- 6.69M
- EPS (ttm)
- -5.01
- Shares out
- 34.66M
- Forward P/E
- -5.83
- YTD return
- -79.02%
- 1-year return
- -85.91%
- Volume
- 16.30K
- Avg volume
- 197.78K
- Open
- 0.94
- Previous close
- 0.9598
- Day's range
- 0.9111 – 0.97
- 52-week range
- 0.62 – 9.60
- Price target
- 12.75 (+1250.3%)
- Earnings date
- Aug 7, 2024
6M -0.2958 (-23.85%)
Key statistics
- Enterprise value
- 71.72M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 25.93
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -470.00K
- Total cash
- 7.83M
- Total debt
- 1.56M
- Return on equity
- -267.86%
- Short % of float
- 9.48%
- 50-day average
- 2.74
- 200-day average
- 5.70
Analyst view
Price target (mean) 12.75 +1250.3% upside
Now 0.9442
- Target (low)
- 11.00
- Target (mean)
- 12.75
- Target (high)
- 16.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.07.
Financials — quick view
FBLG Revenue — quarterly 0
FBLG Net income — quarterly -4.12M
FBLG EPS — quarterly -0.66
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.08 | -0.08 | 0.00 | 0.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.09 | — | — | — |
| Aug 7, 2024 | Jun 1, 2024 | -0.09 | -0.09 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | Rodman & Renshaw | init | — | Buy |
| Nov 20, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 13, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 30, 2024 | HC Wainwright & Co. | init | — | Buy |
| Oct 18, 2024 | EF Hutton | main | Buy | Buy |
About FibroBiologics, Inc.
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fibrobiologics.com
News
FibroBiologics Secures European Patent Covering Methods Of Preparing Fibroblasts To Home To Tumors And Carry Oncolytic Viruses And Other Anti-Cancer Agents 
FibroBiologics Announces Grant of European Patent for Fibroblast Delivery of Tumor Inhibitory Agents 
FibroBiologics Reports Preclinical Data Showing FSdC Spheroids Best Preserve Disc Height In Rabbit Degenerative Disc Disease Model 
FibroBiologics Says IP Australia Issues Notice Of Acceptance For Australian Patent Application Titled ‘Cellular Blend For The Regeneration Of Chondrocytes Or Cartilage Type Cells’ 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
FibroBiologics Files U.S. Patent Application For New Cell-Based Technology Designed To Continuously Produce Peptides Such As GLP-1, GIP and GLP-2 In The Body 
EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections - 12 Health Care Stocks Moving In Friday's After-Market Session
FibroBiologics Receives European Patent Titled Methods Of Enhancing Fibroblast Therapeutic Activity - 12 Health Care Stocks Moving In Friday's After-Market Session
Your note
Sign in to keep a note on FBLG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KHOJA HAMID | Officer | Purchase | Aug 11, 2024 | 11,250 |
| O'HEERON PETER | Chief Executive Officer | Stock Gift | Dec 8, 2024 | 5,906,650 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 5.07% | 1,756,593 | 3.69M | Sep 29, 2024 |
| Vanguard Group Inc | 2.23% | 771,444 | 1.62M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.73% | 599,760 | 1.26M | Sep 29, 2024 |
| State Street Corporation | 1.37% | 475,837 | 999.26K | Sep 29, 2024 |
| Cascade Financial Partners, LLC | 0.87% | 302,601 | 635.46K | Sep 29, 2024 |
| Northern Trust Corporation | 0.61% | 210,473 | 441.99K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.81% | 627,676 | 1.32M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.18% | 407,674 | 856.12K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.75% | 259,500 | 544.95K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.75% | 259,295 | 544.52K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 0.44% | 152,807 | 320.89K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.41% | 142,802 | 299.88K | Oct 30, 2024 |